// App-Quantinova.ai

: Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study

Researchers

Presenter

  • Robin Osterhout

Principal Investigators

  • Kristin B. Highland

  • Robert P. Frantz

  • David Nickle

  • John Mcconnell

  • Charles D. Burger

  • Robert F. Roscigno

  • Matt Cravets

  • Ramona Mccaffrey

  • Lawrence S. Zisman

  • Jean-Marie Bruey

  • Luke S. Howard

Medical Centers

  • Norton Pulmonary Specialists, Louisville, KY, United States of America

  • Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, FL, United States of America

  • 1Cardiovascular Diseases, Mayo Clinic Rochester MN United States

  • Imperial College, London, United Kingdom

  • Gossamer Bio, Inc., San Diego, CA, United States of America

  • Respiratory Institute, Cleveland Clinic, Cleveland, OH, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Colony stimulating factor 1 receptor

Drug/Treatment

  • Seralutinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Multicenteric

  • Controlled

Phase

  • I

Study Id's

  • NCT04456998

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved